Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 11, Number 6—June 2005

Research

Emergence and Spread of Streptococcus pneumoniae with erm(B) and mef(A) Resistance

David J. Farrell*Comments to Author , Stephen G. Jenkins†, Steven D. Brown‡, Manish Patel§, Bruce S. Lavin§, and Keith P. Klugman¶#
Author affiliations: *G.R. Micro Ltd, London, United Kingdom; †Mount Sinai School of Medicine, New York, New York, USA; ‡Clinical Microbiology Institute, Wilsonville, Oregon, USA; §sanofi-aventis, Bridgewater, New Jersey, USA; ¶Emory University, Atlanta, Georgia, USA; #University of the Witwatersrand, Johannesburg, South Africa

Main Article

Table 3

Proportion of erythromycin-resistant Streptococcus pneumoniae isolates collected from years 1 to 3 of the PROTEKT US study that exhibit the dual mef(A)+erm(B) genotype according to source of isolate*

Source of isolate No. erm(B)+mef(A)–positive/no. erythromycin-resistant (%)
Year 1 Year 2 Year 3
BAL 35/346 (10.1) 47/349 (13.5) 74/426 (17.4)
Blood 24/805 (3.0) 31/568 (5.5) 37/641 (5.8)
CSF 1/2 (50.0)
Ear 67/420 (16.0) 48/246 (19.5) 107/354 (30.1)
Eye 3/16 (18.8) 11/120 (9.2) 2/7 (28.6)
MEF 2/34 (5.9) 6/29 (20.7) 14/40 (35.0)
NAP 34/246 (13.8) 43/242 (17.8) 51/235 (21.7)
Sinus 18/162 (11.1) 15/159 (9.4) 36/180 (20.0)
Sputum 117/1,056 (11.1) 129/1,050 (12.3) 199/1,294 (15.4)
Throat 1/15 (6.7) 1/8 (12.5)
Not specified 3/33 (9.1) 3/20 (15.0)
Total 304/3,133 (9.7) 335/2,793 (12.0) 520/3,177 (16.4)

*BAL, bronchoalveolar lavage; CSF, cerebrospinal fluid; MEF, middle-ear fluid; NAP, nasopharyngeal swab or aspirate; –, no isolates collected.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO